Filed under: Stocks to Buy

The choppy/consolidating (or perhaps worse) market conditions sometimes give the impression that growth plays do not exist, but that is not the case, and one growth company worth reviewing is Elan Corp. Note: Elan is appropriate only for investors who can tolerate high-risk.

Elan Corp. (NYSE: ELN) is a neuroscience-based technology company focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases and severe pain.

Analysts sees 33-40% revenue growth for Elan in 2008 after likely 30-35% growth in 2007.

Analysts also like Elan’s ramping sales for drug Tysabri for multiple sclerosis and Crohn’s disease; they are also hopeful about the company’s Alzheimer drug, bapineuzmab, currently in trials.

Continue reading Elan Corp. always has the mind on its mind

Permalink | Email this | Comments

Share This

This entry was posted on Friday, February 8th, 2008 at 12:58 pm and is filed under Stocks Money News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.